Detecting cancer cells in frozen ovarian or testicular tissue from children with neuroblastoma or Ewing sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares two molecular tests, RT-qPCR and droplet digital PCR (ddPCR), for detecting minimal residual disease of neuroblastoma and Ewing sarcoma in cryopreserved ovarian and testicular tissue. Tissue samples will be collected and analyzed at the University Hospital Clermont-Ferrand, including samples from prepubertal patients diagnosed in infancy and control tissues from adults undergoing benign procedures. Each sample will be examined with both methods to compare analytical sensitivity and specificity for tumor-specific markers. The findings will help determine which method more reliably identifies rare tumor cells that could cause relapse if gonadal tissue is later transplanted.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women of any age diagnosed with a benign cyst requiring laparoscopy may be included.
* Men of any age diagnosed with a non-obstructive azoospermia may be included.
* Prepubertal girls and boys diagnosed with neuroblastoma or Ewing sarcoma during infancy may be included.
* Capable of providing written informed consent to participate in the research study
* Affiliated with a social welfare service.
* For prepubertal patients, written informed consent to participate in the research study must be provided by their parents or legal guardians.

Exclusion Criteria:

* None

Where it's running

• University hospital
  Clermont-Ferrand, Auvergne, France Recruiting

Study contacts

• Principal investigator: Florence BRUGNON, MD, PhD, HDR — University Hospital, Clermont-Ferrand
• Study coordinator: Lise Laclautre
• Email: drci@chu-clermontferrand.fr
• Phone: 04 73 75 11 95

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized B7-H3 CAR T cells combined with PRAME antigen-specific T cells for relapsed embryonal tumors

  This trial tests a combined personalized B7-H3 CAR T cell and PRAME-specific T cell infusion after lymphodepleting chemotherapy in children and young adults with relapsed or refractory embryonal tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT07172958

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Using silmitasertib with chemotherapy for relapsed solid tumors

  This study is testing a new drug called silmitasertib combined with chemotherapy to see if it helps people with relapsed solid tumors feel better and manage their cancer.

  Recruiting at 24 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 23 other locations · NCT06541262

• Eflornithine (DFMO) plus AMXT 1501 for neuroblastoma, CNS tumors, and sarcomas

  This trial tests whether adding the oral drug AMXT 1501 to oral DFMO can help children and young adults (diagnosed by age 21) with relapsed or refractory neuroblastoma, ETMR, ATRT, Ewing sarcoma, osteosarcoma, or newly diagnosed DIPG.

  Recruiting at 14 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 13 other locations · NCT06465199

• Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients

  This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.

  Recruiting at 70 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 70 other locations · NCT06395103

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.